August 24, 2021

Innovative testing system speeds the development of antiparasitic drugs

INVENesis, a Neuchâtel-based biotech firm founded by former Novartis employees, teamed up with INRAE and CSEM to develop a novel testing system for developing antiparasitic treatments. The research was funded in part by the Canton of Neuchâtel and Innosuisse. Several leading animal-health businesses have already expressed an interest in the technology. The new invention comes at a critical time, since a growing number of parasites are becoming resistant to existing drugs.

Scientist wearing purple gloves
Lucien Rufener, INVENesis and Sarah Heub, CSEM

“Roundworms literally have to keep swimming to stay alive in animals’ digestive tracts,” says Lucien Rufener, CEO of INVENesis. “But with most methods currently used to develop dewormers, the roundworms are inactive and just sit at the bottom of the test plate.” The INVENesis system, on the other hand, prompts the worms to swim from one point to another. “That lets scientists observe how a drug candidate affects the way the parasite moves and immediately eliminate those that wouldn’t be effective inside an animal.”

Press release